Trial to Determine the Efficacy/Safety of Plitidepsin vs Control in Patients With Moderate COVID-19 Infection

NCT04784559 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

205

Enrollment

INDUSTRY

Sponsor class

Stopped Sponsor has decided to end the study prematurely based on significant difficulties in the recruitment of patients, despite the implementation of corrective measures that still failed to increase the accrual rate required for a feasible completion.

Conditions

COVID-19 Infection

Interventions

DRUG: Plitidepsin
DRUG: Dexamethasone
DRUG: Remdesivir
DRUG: Favipiravir

Sponsor

PharmaMar